Military prosecutors say they’ll call as many as 20 witnesses for the sentencing of Army Pfc. …read more
Source: FULL ARTICLE at Fox US News
Tag Archives: GI
Judge continues deliberating in court-martial of GI who gave US secrets to WikiLeaks
A military judge continues deliberating in the court-martial of an Army private charged with aiding the enemy for giving U.S. secrets to WikiLeaks. …read more
Source: FULL ARTICLE at Fox US News
Horizon Science Achieves EFSA Status for Benecarb
By Business Wirevia The Motley Fool
Filed under: Investing
Horizon Science Achieves EFSA Status for Benecarb
Blood glucose lowering ingredient to be marketed in Europe
MELBOURNE, Australia–(BUSINESS WIRE)– Australian company Horizon Science is celebrating another important milestone for its value added food ingredient Benecarb, which has received approval to be marketed in Europe.
The European Food Safety Authority has determined that Benecarb’s safety profile is substantially equivalent to molasses, creating immediate market opportunities for European food and beverage manufacturers. Benecarb has previously secured GRAS (Generally Recognised As Safe) status in the US.
Benecarb has been proven to significantly lower the blood glucose response to carbohydrate intake. Benecarb has a significantly higher ORAC1 value compared to green tea, providing a high source of natural polyphenols and antioxidants. Benecarb can be applied to a wide range of carbohydrate matrices in different food and beverage applications, improving blood glucose response and thus providing healthier carbohydrate metabolism. It can be used in a wide range of foods including cereals, baked goods, soft drinks, juices, energy drinks, meal replacement bars and sweeteners.
Horizon Science‘s first commercial application of Benecarb is LoGiCane™, the world’s first all-natural low GI cane sugar, making it a healthier alternative to normal sugar. Recent testing at Oxford Brookes University—an internationally accredited GI testing facility operating to ISO standards—has shown Benecarb reduces the GI of a sugar from 71 (high GI) to 50 (low GI), a 30 per cent reduction versus the sugar tested without Benecarb.
“Achieving EFSA status for Benecarb creates a significant commercial opportunity for Horizon Science to license its patented ingredients to food and beverage manufacturers seeking to improve the nutritional health profile of their products,” said Arvind Sridharan, CEO, Horizon Science.
Horizon Science Director David Sinclair, Professor, Genetics Department at Harvard Medical School, said, “Polyphenols are increasingly being seen to address consumer health issues, and are a major driver of innovation in the food and beverage manufacturing space.”
Gunnar Weikert, Horizon Science Director and Chairman of Inventages, one of the world’s largest life-sciences, nutrition and wellness focused venture capital funds, said, “As the rate of obesity and diabetes increases around the globe, products like Benecarb can help improve consumers’ diet and help them live a healthier lifestyle. Our investment in Horizon Science is being validated by recent initiatives of large food and beverage manufacturers to lower the glycemic impact of their products.”
From: http://www.dailyfinance.com/2013/04/17/horizon-science-achieves-efsa-status-for-benecarb/
Layoffs at Resident Evil: Operation Raccoon City Dev
Layoffs have hit Resident Evil: Operation Racoon City developer Slant Six Games. According to a company statement, the layoffs are “temporary” as it seeks new projects, and the plan is to re-hire as many employees as possible once that happens.
Slant Six confirmed that layoffs, providing the following statement to GI.biz:
“This necessary measure has been taken to reduce the size of our team and to decrease interim operating costs while we continue to negotiate new business. Temporary layoffs provide us with a time period to keep everyone’s employment position open with full benefits. The intention is to reinstate all of the people affected when new projects or funding has been secured.”
Source: FULL ARTICLE at IGN Video Games
The Role Medication Plays in Treating Obesity
By Max Macaluso, Ph.D., The Motley Fool
Filed under: Investing
Last summer, the Food and Drug Administration approved two new medications for the treatment of obesity. VIVUS‘ Qsymia has already reached the market, while Arena Pharmaceuticals‘ Belviq will be launched by its commercialization partner Eisai once the drug clears DEA scheduling. A third player, Orexigen Therapeutics , is still developing its drug Contrave. The fact that obesity affects more than a third of American adults today has attracted many biotech investors to these stocks, but many may not fully understand how physicians approach treatment for this disease. For instance, are exercise and diet all patients really need to manage their weight?
To help clarify this complex topic, Motley Fool health-care analyst Max Macaluso spoke with Dr. Domenica Rubino, a weight-management expert and representative of The Obesity Society. In the following segment from their discussion, Dr. Rubino discusses the role that drugs play in treating obesity. A transcript follows the video.
What macro trend was Warren Buffett referring to when he said “this is the tapeworm that’s eating at American competitiveness”? Find out in our free report: “What’s Really Eating at America’s Competitiveness.” You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The relevant video segment can be found between 5:20 and 8:17.
Max Macaluso: Let’s pivot the discussion to drugs and treatment now. Arena recently got Belviq approved. It’s not on the market yet. Vivus got Qsymia approved, and Orexigen is still developing Contrave. What role do drugs really play in treatment?
Dr. Domenica Rubino: A fundamental thing to understand is that the physiology of obesity is actually very complicated. Just as I was saying there are multiple causes of obesity, there are multiple factors that protect weight.
What people don’t really understand is that the body is totally focused on holding onto weight, at all costs. People like to say, “Well, you just eat less, move more.” It’s not as simple as that, because when we do lose weight — and countless people who struggle with this lose weight — there are a lot of mechanisms that kick in.
There are endocrine signals coming from the fat cells, muscle cells, the GI tract, all to the brain to say, “Hold onto that weight.”
What happens to that person is they get hungrier, they don’t really want to move, certain foods look much more appealing, certain parts of the brain are lighting up, thinking, “Oh, I want that.”
What else can happen is that people start to lose their sense of portion. The same subject, before weight loss and after weight loss, will not be able to estimate that portion anymore. Your body is in full-court press to regain weight.
That’s where these medications can be really helpful. They augment our toolbox, as physicians, because primarily what we work with is helping people make lifestyle changes, identifying those factors that I was talking about.
Do they have sleep apnea? …read more
Source: FULL ARTICLE at DailyFinance
Chaplain gets Medal of Honor 62 years after death
In the cold, barren hills of Korea more than 60 years ago, two teary-eyed soldiers stood in a prisoner of war camp where their chaplain lay dying.
The Rev. Emil Kapaun was weak, his body wracked by pneumonia and dysentery. After six brutal months in the hellish camp, the once sturdy Kansas farmer’s son could take no more. Thousands of soldiers had already died, some starving, others freezing to death. Now the end was near for the chaplain.
Lt. Mike Dowe said goodbye to the man who’d given him hope during those terrible days. The young West Point grad cried, even as the chaplain, he says, tried to comfort him with his parting words: “Hey, Mike, don’t worry about me. I’m going to where I always wanted to go and I’ll say a prayer for all of you.”
Lt. Robert Wood wept, too, watching the Roman Catholic chaplain bless and forgive his captors. He helped carry Kapaun out of the mud hut and up a hill on a stretcher after Chinese soldiers ordered he be moved to a hospital, a wretched, maggot-filled place the POWs dubbed “the death house.” There was little or no medical care there. Kapaun died on May 23, 1951.
These two soldiers — and many more — never forgot their chaplain. Not his courage in swatting away an enemy soldier pointing a gun at a GI‘s head. Not his talent for stealing food, then sneaking it to emaciated troops. Not the inspiring way he rallied his “boys,” as he called them, urging them to keep their spirits up.
The plain-spoken, pipe-smoking, bike-riding chaplain was credited with saving hundreds of soldiers during the Korean War. Kapaun (pronounced Kah-PAHWN) received the Distinguished Service Cross and many other medals. His exploits were chronicled in books, magazines and a TV show. A high school was named for him. His statue stands outside his former parish in tiny Pilsen, Kan.
But one award, the Medal of Honor, always remained elusive.
Dowe and other POWs had lobbied on and off for years, writing letters, doing interviews, enlisting support on Capitol Hill. Dowe’s recommendation was turned down in the 1950s.The campaign stalled, then picked up steam decades later. Kapaun’s “boys” grew old, their determination did not.
Now it has finally paid off.
On April 11, those two young lieutenants, Dowe and Wood, now 85 and 86, will join their comrades, Kapaun’s family and others at the White House where President Barack Obama will award the legendary chaplain the Medal of Honor posthumously.
“It is about time,” Dowe says.
Even now, Father Kapaun‘s story may still have one final chapter: sainthood.
The Korean conflict is sometimes called “the forgotten war,” overshadowed by the global cataclysm of World War II and the nation’s long struggle in Vietnam.
For veterans, though, there are vivid war memories: the desperation of eating weeds plucked from the dirt, the horror of discovering buddies who’d died overnight, the evanescent joy of taking a few puffs on their chaplain’s pipe. Many men of the 3rd Battalion, 8th Cavalry regiment, credit Kapaun for their survival, …read more
Source: FULL ARTICLE at Fox US News
POZEN Announces Results from a Burden of Cardiovascular Disease Study: a Managed Care Perspective
By Business Wirevia The Motley Fool
Filed under: Investing
POZEN Announces Results from a Burden of Cardiovascular Disease Study: a Managed Care Perspective
Presentation at AMCP Demonstrates Cost Reduction When PPI Used in Combination With Aspirin for Both Commercial and Medicare Populations
CHAPEL HILL, N.C.–(BUSINESS WIRE)– POZEN Inc. (Nasdaq: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced the results of a POZEN sponsored study at the Academy of Managed Care Pharmacy’s 25th Annual Meeting and Expo on April 4, 2013. Ryan S. Clark, Pharm.D., MBA, Health Outcomes and Managed Markets Fellow, Global Health Economics & Outcomes Research at Xcenda, presented the abstract, The Burden of Secondary Cardiovascular Disease in Commercial and Medicare Patients: A Managed Care Perspective. The secondary prevention of cardiovascular events includes the daily use of aspirin. Chronic aspirin therapy is associated with significant gastrointestinal (GI) toxicity including dyspepsia, gastric ulcers and GI bleeding, all of which contribute to the disease and cost burden of secondary prevention. The GI toxicity of aspirin can be mitigated by the use of proton pump inhibitors (PPIs). The Xcenda analysis demonstrated that the prevention of cardiovascular events with aspirin, plus a PPI, compared to aspirin alone is associated with a net per-patient per-year cost decrease of $103 and $145 and a potential overall cost decrease of $1.8 million and $11.0 million for a typical one million-member Commercial and Medicare Plan, respectively.
“The overall cost of secondary cardiovascular events in patients with a history of coronary heart disease, transient ischemic attack, or ischemic stroke represents a significant financial burden on managed care,” said Rashad Carlton, Pharm.D., MSPH, Assistant Director, Global Health Economics & Outcomes Research at Xcenda. “Despite American College of Cardiology and American Heart Association guideline recommendations to start aspirin therapy and continue indefinitely in all patients unless contraindicated, aspirin remains underutilized.”
About the Study
The primary objective of the study was to characterize the financial burden of secondary cardiovascular disease and its long-term complications in patients at risk for a secondary cardiovascular event.
An economic model designed to yield the annual secondary cardiovascular disease cost burden was constructed using literature-based population, medication discontinuation/non-adherence, and cardiovascular event incidence data. Care records of secondary cardiovascular disease patients were reviewed based on treatment either with aspirin, aspirin + PPI, or no aspirin. Secondary events were calculated based on annual recurrence rates adjusted for treatment discontinuation/non-adherence. The treatment cohort cost per member and …read more
Source: FULL ARTICLE at DailyFinance
Remove Duplicate Two Line Pairs?
By bakere19
So I have a bunch of files that look like this
Code:
>gi|33332323
MMKCRGVIMVVEKVMKRDGRIVPFDESRIRWAVQ---
>gi|45235353
MMKCR----VEKMRDVFFDESIRWAVQ
They go on…sequences are much longer but all in two line (fasta) format.
I want to remove duplicate pairs of ID(GI) number and sequence. I tried using grep “>” to get all the header lines, then sort -u > uniquegilist. Then I wrote the loop
Code:
for x in `cat uniquegilist`; do grep -m 1 -A1 $x sequencefile;done
I’m not sure why it didn’t work, but that just returned the list of unique GI numbers and didn’t include the sequences.
Any ideas on how to grab the unique GI # and sequence together…preferably preserving format?
…read more
Source: FULL ARTICLE at The UNIX and Linux Forums
Gears of War Creator on Console Restrictions
Former Epic Games designer Cliff Bleszinski, who left the Gears of War developer in 2012, believes the gaming industry is in a state of turmoil. Speaking to GI.biz, Bleszinski said, “This business has not been in a state of transition like it is right now since the video game crash of the ’80s.”
Bleszinski continued, “I think Nintendo could possibly be faced with the situation of becoming a company that only makes software moving forward. I think Sony and Microsoft are about to come to major blows. But at the same time, people love playing games on their iPad. The PC is going through a wonderful renaissance right now. I think we’re ready to do digital download games all the time.”